Damon Race/LinkedIn
Jun 25, 2026, 15:28
Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared a post on LinkedIn:
“Met up with my friends from ReciPharm Advanced Bio at BIO International 2026.
ReciPharm is a wonderful partner in our efforts to advance GENV-HEM, the first gene therapy with durable expression biology for patients with hemophilia A with or without inhibitors.
A special thank you to Greg Behar and Jhomar Marquez.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 22:47Avirup Guha: Early Immune Responses to Androgen Deprivation Therapy and Coronary Plaque Progression
-
Nov 9, 2026, 22:42Angela Forsyth: Joining Novo Nordisk as Medical Liaison for the Ohio Valley Region
-
Nov 9, 2026, 22:36Vladimir Otasevic: Presenting Thromboprophylaxis and Treatment of VTE in Patients With Malignancy
-
Nov 9, 2026, 22:28Dragoș Claudiu Popescu: Corticosteroid Exposure and Thrombotic Risk in ITP
-
Nov 9, 2026, 22:20Cedric Ghevaert: How RNA Processing Defects Affect Megakaryocytes in TAR Syndrome
-
Nov 9, 2026, 22:07Todd C. Villines: PARAMOUNT Shows Benefits of Coronary Plaque-Based Care in Stable Symptomatic Patients
-
Nov 9, 2026, 22:06Maxima Mendez: Complete Results of the Pelacarsen Cardiovascular Outcomes Study at AHA 2026
-
Nov 9, 2026, 22:04The Role of the Spleen in Inflammation During Acute Plasmodium Vivax Malaria – American Journal of Hematology
-
Nov 9, 2026, 21:52Behnood Bikdeli: Honored to Share the Stage at AHA 2026 to Discuss Grant Funding